This is a summary. To read the whole story subscribe to BostonGlobe.com
Biogen Idec, one of world’s oldest biotech companies, has a history of resiliency in an industry where failures and mergers are common. It’s been a fixture on the Globe 100, appearing 18 times over the past quarter century, more than any other biotechnology company that remains independent today.
Biogen Idec earned a spot as the number eight company on this year’s list. Since George Scangos became chief executive three years ago, the company’s stock market value has quadrupled to $49 billion — jousting with EMC for the claim to be the Bay State’s most valuable publicly traded company. And both Biogen Idec’s revenue and profits have risen for four straight years. Last year alone, it earned $1.4 billion in profits on $5.5 billion in revenue.